Practical management of patients with chronic myeloid leukemia receiving imatinib

Michael W.N. Deininger, Stephen G. O'Brien, John M. Ford, Brian J. Druker

Research output: Contribution to journalReview article

290 Scopus citations

Abstract

The introduction of imetinib, a specific inhibitor of the Bcr-Abl tyrosine kinase, has dramatically changed the management of chronic myeloid leukemia (CML). More than 10,000 patients worldwide have been treated with imatinib in clinical trials, and a large body of information has accumulated about the use of this drug. The purpose of this article is to review practical guidelines in regard to optimal dosing, monitoring, managing common side effects such as myelosuppression, and potential drug interactions. The treatment recommendations are intended to optimize therapy with imatinib while taking into account a patient's specific circumstances.

Original languageEnglish (US)
Pages (from-to)1637-1647
Number of pages11
JournalJournal of Clinical Oncology
Volume21
Issue number8
DOIs
StatePublished - Apr 15 2003
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Practical management of patients with chronic myeloid leukemia receiving imatinib'. Together they form a unique fingerprint.

  • Cite this